Exelixis (EXEL) said Wednesday it received approval for Cabometyx for patients with previously treated advanced neuroendocrine tumors from the US Food and Drug Administration.
The approval was for the treatment of patients 12 years of age and older with previously treated, unresectable, pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
The company said the approval was based on a phase 3 trial that showed a statistically significant and clinically meaningful improvement in progression-free survival in patients with the treatment compared with those with a placebo.
Price: 37.41, Change: -0.30, Percent Change: -0.81
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。